Grace Therapeutics (GRCE) announced details of the Company’s Type C meeting with the U.S. Food and Drug Administration. The purpose of this meeting was to obtain FDA feedback on the completed Phase 3 STRIVE-ON safety trial of GTx-104 and its planned New Drug Application submission including clinical, non-clinical, and chemistry, manufacturing, and control requirements. Based on feedback from the FDA, the Company believes that the data and regulatory packages as currently structured will be sufficient for submission of an NDA.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRCE:
- Grace Therapeutics Reports Q3 Progress and Financial Results
- Grace Therapeutics Files Form S-3 for Flexible Securities Offering
- Grace Therapeutics files to sell 8.84M shares of common stock for holders
- Promising Potential of Grace Therapeutics’ GTX-104 Drives Buy Rating
- Grace Therapeutics reports Q3 EPS (36c), consensus (46c)